alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM DAY
INTERNATIONAL GROUP, INC'S ANNUAL REPORT ON FORM 10K FOR THE YEAR ENDED DECEMBER
31, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10K.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                             508
<SECURITIES>                                         0
<RECEIVABLES>                                   37,381
<ALLOWANCES>                                     2,141
<INVENTORY>                                     32,831
<CURRENT-ASSETS>                                75,410
<PP&E>                                          91,560
<DEPRECIATION>                                  21,821
<TOTAL-ASSETS>                                 331,504
<CURRENT-LIABILITIES>                           41,750
<BONDS>                                        276,469
<PREFERRED-MANDATORY>                           41,745
<PREFERRED>                                     39,711
<COMMON>                                             1
<OTHER-SE>                                    (89,429)
<TOTAL-LIABILITY-AND-EQUITY>                   331,504
<SALES>                                        198,418
<TOTAL-REVENUES>                               198,418
<CGS>                                          123,336
<TOTAL-COSTS>                                  165,557
<OTHER-EXPENSES>                                   504
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              28,085
<INCOME-PRETAX>                                  4,272
<INCOME-TAX>                                     2,021
<INCOME-CONTINUING>                              2,251
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  (857)
<CHANGES>                                            0
<NET-INCOME>                                     1,394
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
<PAGE>

                                                                    EXHIBIT 99.4

                                  CERTIFICATION
                       PURSUANT TO 18 U.S.C. SECTION 1350,
           AS ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         I, Bjorn Olafsson, as Executive Vice President and Chief Financial
Officer of Nera ASA (the "Company"), certify, pursuant to 18 U.S.C.ss. 1350, as
adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

         (3)      the accompanying Form 20-F report for the period ending
                  December 31, 2002 as filed with the U.S. Securities and
                  Exchange Commission (the "Report") fully complies with the
                  requirements of Section 13(a) or 15(d) of the Securities
                  Exchange Act of 1934, as amended; and

         (4)      the information contained in the Report fairly presents, in
                  all material respects, the financial condition and results of
                  operations of the Company.

Dated: June 26, 2003

                            /s/ BJORN OLAFSSON
                            ------------------------------
                            Bjorn Olafsson
                            Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
U.S. Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely to accompany this Report
pursuant to 18 U.S.C. ss. 1350, and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, and is not to be
incorporated by reference into any filing of the Company, whether made before or
after the date hereof, regardless of any general incorporation language in such
filing.

                                      109
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>


<ARTICLE>                                      9
<CIK>                         0000814178
<NAME>                        MATTHEW L. BURNS
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-1998
<PERIOD-START>                                 JAN-01-1998
<PERIOD-END>                                   JUN-30-1998
<CASH>                                         2,703
<INT-BEARING DEPOSITS>                         0
<FED-FUNDS-SOLD>                               2,738
<TRADING-ASSETS>                               0
<INVESTMENTS-HELD-FOR-SALE>                    7,130
<INVESTMENTS-CARRYING>                         10,242
<INVESTMENTS-MARKET>                           10,324
<LOANS>                                        67,893
<ALLOWANCE>                                    756
<TOTAL-ASSETS>                                 94,500
<DEPOSITS>                                     77,935
<SHORT-TERM>                                   1,058
<LIABILITIES-OTHER>                            638
<LONG-TERM>                                    5,493
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       965
<OTHER-SE>                                     8,411
<TOTAL-LIABILITIES-AND-EQUITY>                 94,500
<INTEREST-LOAN>                                3,115
<INTEREST-INVEST>                              487
<INTEREST-OTHER>                               109
<INTEREST-TOTAL>                               3,711
<INTEREST-DEPOSIT>                             1,459
<INTEREST-EXPENSE>                             1,668
<INTEREST-INCOME-NET>                          2,043
<LOAN-LOSSES>                                  420
<SECURITIES-GAINS>                             0
<EXPENSE-OTHER>                                1,551
<INCOME-PRETAX>                                281
<INCOME-PRE-EXTRAORDINARY>                     177
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   177
<EPS-BASIC>                                    0.92
<EPS-DILUTED>                                  0.92
<YIELD-ACTUAL>                                 0
<LOANS-NON>                                    478
<LOANS-PAST>                                   0
<LOANS-TROUBLED>                               0
<LOANS-PROBLEM>                                0
<ALLOWANCE-OPEN>                               636
<CHARGE-OFFS>                                  329
<RECOVERIES>                                   29
<ALLOWANCE-CLOSE>                              756
<ALLOWANCE-DOMESTIC>                           756
<ALLOWANCE-FOREIGN>                            0
<ALLOWANCE-UNALLOCATED>                        177
        


</TABLE>
[No. 21283-8-II.

Division Two.

January 16, 1998.]

#### James A. Cenci, et al., *Petitioners,*v. Marvin Lee Timm, et al., *Respondents.*

Appeal from a judgment of the Superior Court for Pierce County, No. 96-2-08996-1, Fred Fleming, J., entered October 1, 1996. *Affirmed*by unpublished opinion per Morgan, J., concurred in by Seinfeld and Armstrong, JJ.
09-1415-cr

United States v. Lee Cho UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT SUMMARY ORDER R ULINGS BY SUMMARY ORDER DO NOT HAVE PRECEDENTIAL EFFECT . C ITATION TO A SUMMARY ORDER FILED ON OR AFTER J ANUARY 1, 2007, IS PERMITTED AND IS GOVERNED BY F EDERAL R

ULE OF A PPELLATE P ROCEDURE 32.1 AND THIS COURT ’ S L OCAL R ULE 32.1.1. WHEN CITING A SUMMARY ORDER IN A DOCUMENT FILED WITH THIS COURT , A PARTY MUST CITE EITHER THE F EDERAL A PPENDIX OR AN ELECTRONIC DATABASE ( WITH THE NOTATION “ SUMMARY ORDER ”). A PARTY CITING A SUMMARY ORDER MUST SERVE A COPY OF IT ON ANY PARTY NOT REPRESENTED BY COUNSEL . At a stated term of the United States Court of Appeals for the Second Circuit, held at the Daniel Patrick Moynihan United States Courthouse, 500 Pearl Street, in the City of New York, on the 5 day of February, two thousand ten.

th PRESENT: RALPH K. WINTER, JOHN M. WALKER, JR., ROSEMARY S. POOLER,

Circuit Judges. -------------------------------------------X UNITED STATES OF AMERICA, Appellee,

- v. - No. 09-1415-cr SUN LEE CHO, Defendant-Appellant. -------------------------------------------XAPPEARING FOR LABE M. RICHMAN, New York, NY.

DEFENDANT-APPELLANT: APPEARING FOR APPELLEE: JUSTIN ANDERSON, Assistant United States Attorney, Of Counsel (Preet Bharara, United States Attorney, Katherine Polk Failla, Assistant United States Attorney, Of Counsel, on the brief ), Southern District of New York, New York, NY.

Appeal from a judgment of the United States District Court for the Southern District of New York (Sullivan, J.). ON CONSIDERATION WHEREOF, IT IS HEREBY ORDERED, ADJUDGED, AND DECREED that the judgment of the district court be and hereby is AFFIRMED . Appellant Cho appeals from a judgment of conviction following her plea of guilty to one count of bank fraud, in violation of Title 18, United States Code, Section 1344. Her sole challenge is to the district court’s order of restitution in the amount of $49,600. Cho attempted to make restitution in full prior to the entry of the district court’s judgment and, based on her belief that she was successful, sought for the judgment to be entered without an order of restitution. The district court found that restitution was not completed prior to entry of the judgment and denied Cho’s request. The district court also denied a subsequent request by Cho that “a new judgment be issued without the restitution order.” For substantially the reasonsrelied upon by the district court, the district court’s judgment

of conviction and subsequent order are AFFIRMED .

FOR THE COURT: Catherine O’Hagan Wolfe, Clerk
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1690 Nitrogen gas analyzer. ( a ) *Identification.* A nitrogen gas analyzer is a device intended to measure the concentration of nitrogen in respiratory gases to aid in determining a patient's ventilatory status. The device may use techniques such as gas chromatography or mass spectrometry.
( b ) *Classification.* Class II (performance standards).
#### Carl Gerr *v.*Yale University

*Mitchel W. Garber,*for the appellee (plaintiff).

*Donald F. Keefe,*for the appellant (defendant).

Argued November 5

decided November 6, 1968

The motion by the plaintiff for review of the decision of this court denying his motion for permission to file an appendix to his brief in the appeal from the Superior Court in New Haven County is denied after hearing.
§ 640.6 Modifications of Whole Blood. Upon approval by the Director, Center for Biologics Evaluation and Research, of a supplement to the biologics license application for Whole Blood a manufacturer may prepare Whole Blood from which the antihemophilic factor has been removed, provided the Whole Blood meets the applicable requirements of this subchapter and the following conditions are met: ( a ) The antihemophilic factor shall be removed in accordance with paragraphs (a), (b), and (c) of § 640.52.
( b ) Although the closed system between the red blood cells and plasma shall be maintained, the red blood cells shall be maintained between 1 and 6 °C at all times, including that time when the plasma is being frozen for removal of the antihemophilic factor.
[38 FR 32089, Nov. 20, 1973, as amended at 49 FR 23834, June 8, 1984; 50 FR 4138, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 59 FR 49351, Sept. 28, 1994; 64 FR 45372, Aug. 19, 1999; 64 FR 56453, Oct. 20, 1999]
ARMED SERVICES BOARD OF CONTRACT APPEALS Appeal of

-- ) ) Sygnetics, Inc. ) ) Under Contract No. W911YN-12-F-0040 ) APPEARANCE FOR THE APPELLANT:
APPEARANCES FOR THE GOVERNMENT: ASBCA No. 59366

Mr. Tony Tarkowski

CEO Raymond M. Saunders, Esq.

Army ChiefTrial Attorney MAJ Nancy J. Lewis, JA

Trial Attorney ORDER OF DISMISSAL The dispute has been settled. The appeal is dismissed with prejudice. Dated: 5 September 2014

TERRENCES.HARTMAN Administrative Judge Armed Services Board ofContract Appeals
I certify that the foregoing is a true copy ofthe Order ofDismissal ofthe Armed Services Board ofContract Appeals in ASBCANo. 59366, Appeal ofSygnetics, Inc., rendered in conformance with the Board's Charter. Dated:

JEFFREY D. GARDIN Recorder, Armed Services Board ofContract Appeals
§ 524.1484c Neomycin, isoflupredone, and tetracaine ointment. ( a ) *Specifications.* The drug contains 5 milligrams of neomycin sulfate (equivalent to 3.5 milligrams of neomycin base), 1 milligram of isoflupredone acetate, and 5 milligrams of tetracaine hydrochloride in each gram of ointment.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* In treatment of otitis externa and other inflammatory conditions of the external ear canal, a quantity of ointment sufficient to fill the external ear canal; may be applied one to three times daily. When used on the skin or mucous membranes, the affected area should be cleansed, and a small amount of the ointment applied and spread or rubbed in gently. The involved area may be treated one to three times a day and these daily applications continued in accordance with the clinical response.
( 2 ) *Indications for use.* For the treatment of acute otitis externa in dogs and to a lesser degree, chronic otitis externa in dogs. It also is effective in treating anal gland infections and moist dermatitis in the dog and is a useful dressing for minor cuts, lacerations, abrasions, and post-surgical therapy in the horse, cat, and dog. It may also be used following amputation of dewclaws, tails and claws, following ear trimming and castrating operations.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 18172, Apr. 28, 1978; 79 FR 10970, Feb. 27, 2014]
Exhibit 32.2

AMENDED AND RESTATED CERTIFICATION PURSUANT TO

18 U.S.C. SECTIONS 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Ebix, Inc. (the Company) for the period ended June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof
(the Report), I, Robert F. Kerris, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



|    |  |                        
|--- |  | -----------------------
|By: |  | /s/ Robert Kerris      
|    |  | Name: Robert Kerris    
|    |  | Chief Financial Officer

January 9, 2012
<PAGE>   1

                                                                   EXHIBIT 10.40

                                 FIRST AMENDMENT

                                       TO

                              EMPLOYMENT AGREEMENT

        THIS FIRST AMENDMENT (this "Amendment") to the Employment Agreement
dated October 18, 1994 (the "Agreement"), between Redhook Ale Brewery,
Incorporated ("Employer") and Paul Shipman ("Employee"), is made effective as of
the date this Amendment has been signed by the Employer and the Employee.
Capitalized terms used but not defined in this Amendment will have the meanings
given those terms in the Agreement.

        1.      Section 7(d) of the Agreement is amended to read as follows in
its entirety:

        d. Restriction on Stock Transfers. Employee shall continuously maintain
ownership of a minimum of two hundred fifty thousand (250,000) shares of
Employer's common stock until the earlier of (i) two (2) years following the
termination of this Agreement, or (ii) September 30, 2001. The number of
restricted shares shall be counted by assuming any stock split, stock dividend,
combination, recapitalization, reclassification or other change in the terms of
common stock occurring after the effective date of this Agreement had not
occurred.

                2.      Except as amended hereby, the Agreement shall remain in
full force and effect.

                3.      This Amendment may be executed in more than one
counterpart, by facsimile signature, each counterpart deemed an original
instrument and such counterparts in the aggregate constituting one and the same
instrument.

        IN WITNESS WHEREOF, the undersigned have executed this First Amendment,
pursuant to Section 12(b) of the Agreement.


                                        "Employer"

Date:  May 6, 1999                      By: /s/ BRADLEY A. BERG
                                           -------------------------------------
                                                Bradley A. Berg

                                        Its: Executive Vice President


                                        "Employee"

Date:  May 6, 1999                      By: /s/ PAUL S. SHIPMAN
                                           -------------------------------------
                                                Paul S. Shipman
<PAGE>

                                                                    EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Evergreen Solar, Inc. (the "Company") on
Form 10-K for the year ended December 31, 2003 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Richard M. Feldt,
Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
Section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.

/s/ Richard M. Feldt
------------------------
Richard M. Feldt
Chief Executive Officer
March 23, 2004
§ 812.47 Emergency research under § 50.24 of this chapter. ( a ) The sponsor shall monitor the progress of all investigations involving an exception from informed consent under § 50.24 of this chapter. When the sponsor receives from the IRB information concerning the public disclosures under § 50.24(a)(7)(ii) and (iii) of this chapter, the sponsor shall promptly submit to the IDE file and to Docket Number FDA-1995-S-0036 in the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, copies of the information that was disclosed, identified by the IDE number.
( b ) The sponsor also shall monitor such investigations to determine when an IRB determines that it cannot approve the research because it does not meet the criteria in the exception in § 50.24(a) of this chapter or because of other relevant ethical concerns. The sponsor promptly shall provide this information in writing to FDA, investigators who are asked to participate in this or a substantially equivalent clinical investigation, and other IRB's that are asked to review this or a substantially equivalent investigation.
[61 FR 51531, Oct. 2, 1996, as amended at 64 FR 10943, Mar. 8, 1999; 88 FR 16880, Mar. 21, 2023]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S CONSOLIDATED FINANCIAL STATEMENTS OF INCOME AND CONSOLIDATED
BALANCE SHEETS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-1997
<PERIOD-END>                               SEP-28-1996
<CASH>                                            6694
<SECURITIES>                                      4963
<RECEIVABLES>                                    77146
<ALLOWANCES>                                      4878
<INVENTORY>                                     110041
<CURRENT-ASSETS>                                207880
<PP&E>                                            8909
<DEPRECIATION>                                    5162
<TOTAL-ASSETS>                                  213258
<CURRENT-LIABILITIES>                           159356
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             6
<OTHER-SE>                                       53896
<TOTAL-LIABILITY-AND-EQUITY>                    213258
<SALES>                                         185736
<TOTAL-REVENUES>                                185736
<CGS>                                           167370
<TOTAL-COSTS>                                   167370
<OTHER-EXPENSES>                                 14132
<LOSS-PROVISION>                                   534
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                   4666
<INCOME-TAX>                                      1740
<INCOME-CONTINUING>                               2926
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      2926
<EPS-PRIMARY>                                      .51
<EPS-DILUTED>                                      .51
        

</TABLE>
This document may contain confidential informatio n and is not available

online or from the USEPA Docket Center.

For a copy of the document, please contact Shirley Fan at

CommercialVesselPermit@epa.gov
White Papers that Address the Subject of Compressors, 

Pneumatic Devices, and Leaks

Attached are the comments of the Texas Pipeline Association to the white papers that address the 

subject of compressors, pneumatic devices and leaks. 

Please contact us at 512/478-2871 or via email at texaspipelineassociation@yahoo.com if you have 

any questions or difficulties with the attachment.

Thank you.

Texas Pipeline Association <texaspipelineassociation@yahoo.com>

Mon 6/16/2014 5:52 PM

To:OilandGas.Whitepapers <OilandGas.Whitepapers@epa.gov>; 

 1 attachment

EPA White Paper Comments_0059.pdf; 

White Papers that Address the Subject of Compressor... - OilandGas.Whitepapers Page 1 of 1

https://pod51045.outlook.com/owa/OilandGas.Whitepapers@epa.gov/ 8/26/2014